I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Prognostic Value of Baseline Medications Plus Neutrophil-to..:
Toshiki Ogiwara
;
Hitoshi Kawazoe
;
Saeka Egami
...
https://www.frontiersin.org/articles/10.3389/fonc.2021.770268/full. , 2021
Link:
https://doi.org/10.3389/fonc.2021.770268
RT Journal T1
Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study
UL https://suche.suub.uni-bremen.de/peid=base-ftdoajarticles:oai:doaj.org_article:b197c72349844806ab490770dcad20f3&Exemplar=1&LAN=DE A1 Toshiki Ogiwara A1 Hitoshi Kawazoe A1 Saeka Egami A1 Hironobu Hashimoto A1 Yoshimasa Saito A1 Naomi Sakiyama A1 Yuichiro Ohe A1 Masakazu Yamaguchi A1 Tetsuya Furukawa A1 Azusa Hara A1 Yui Hiraga A1 Aya Jibiki A1 Yuta Yokoyama A1 Sayo Suzuki A1 Tomonori Nakamura PB Frontiers Media S.A. YR 2021 K1 nivolumab K1 pembrolizumab K1 baseline medications K1 neutrophil-to-lymphocyte ratio K1 prognostic score K1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens K1 RC254-282 JF https://www.frontiersin.org/articles/10.3389/fonc.2021.770268/full LK http://dx.doi.org/https://doi.org/10.3389/fonc.2021.770268 DO https://doi.org/10.3389/fonc.2021.770268 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)